Name: Cagrilintide Guide
Creator: Peppa
Published: 2025-01-15

Cagrilintide — Benefits, Dosing & Protocol GuideA long-acting amylin analog being developed by Novo Nordisk for obesity. Unlike GLP-1 agonists, it mimics amylin to slow gastric emptying and increase satiety. Combined with Semaglutide (CagriSema), it achieved 20.4% weight loss in REDEFINE 1 trial. FDA filing December 2024.Key Benefits

Reduces appetite through amylin pathway

Complements GLP-1 agonist effects (additive)

Slows gastric emptying

Improves glycemic control

Novel mechanism (targets hypothalamus/hindbrain)

Applications: Weight Loss, Metabolism SupportWritten by Peppa at Peptide Upside — the peptide lifestyle guide. Research, calculate, and track your peptide journey.